Nuvalent Files 8-K: Other Events & Exhibits
Ticker: NUVL · Form: 8-K · Filed: Jan 14, 2025 · CIK: 1861560
| Field | Detail |
|---|---|
| Company | Nuvalent, INC. (NUVL) |
| Form Type | 8-K |
| Filed Date | Jan 14, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: current-report, sec-filing, regulatory
TL;DR
Nuvalent filed an 8-K on Jan 13, reporting other events and financials.
AI Summary
Nuvalent, Inc. filed an 8-K on January 14, 2025, reporting an event on January 13, 2025. The filing is a current report under Section 13 or 15(d) of the Securities Exchange Act of 1934. It includes information on "Other Events" and "Financial Statements and Exhibits."
Why It Matters
This 8-K filing indicates Nuvalent is reporting significant events or financial updates that could impact investor understanding of the company's current status.
Risk Assessment
Risk Level: low — This filing is a standard 8-K current report and does not appear to disclose any immediate negative news or significant financial distress.
Key Players & Entities
- Nuvalent, Inc. (company) — Registrant
- January 13, 2025 (date) — Earliest event reported
- January 14, 2025 (date) — Date of report
- 001-40671 (other) — Commission File Number
FAQ
What specific 'Other Events' are being reported by Nuvalent, Inc. in this 8-K filing?
The filing indicates 'Other Events' as an item information, but the specific details of these events are not provided in the excerpt.
What is the significance of filing under Section 13 or 15(d) of the Securities Exchange Act of 1934?
Filing under Section 13 or 15(d) signifies that Nuvalent, Inc. is making a current report to the SEC regarding significant events or changes in the company's operations or financial condition.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on January 13, 2025.
What is Nuvalent, Inc.'s principal executive office address?
Nuvalent, Inc.'s principal executive office is located at One Broadway, 14th Floor, Cambridge, Massachusetts 02142.
What is the SIC code for Nuvalent, Inc.?
The Standard Industrial Classification (SIC) code for Nuvalent, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 451 words · 2 min read · ~2 pages · Grade level 9.7 · Accepted 2025-01-14 06:16:38
Key Financial Figures
- $0.0001 — which registered Class A Common Stock, $0.0001 par value per share NUVL The Nasdaq
Filing Documents
- d908944d8k.htm (8-K) — 23KB
- d908944dex991.htm (EX-99.1) — 25KB
- 0001193125-25-005629.txt ( ) — 175KB
- nuvl-20250113.xsd (EX-101.SCH) — 3KB
- nuvl-20250113_lab.xml (EX-101.LAB) — 18KB
- nuvl-20250113_pre.xml (EX-101.PRE) — 11KB
- d908944d8k_htm.xml (XML) — 4KB
From the Filing
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 NUVALENT, INC. (Exact name of registrant as specified in its charter) Delaware 001-40671 81-5112298 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) Nuvalent, Inc. One Broadway , 14th Floor , Cambridge , Massachusetts 02142 (Address of principal executive offices, including zip code) (857) 357-7000 (Registrant's telephone number, including area code) Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trade Symbol(s) Name of each exchange on which registered Class A Common Stock, $0.0001 par value per share NUVL The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ( 240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item8.01. Other Events. On January 13, 2025, Nuvalent, Inc. (the "Company") issued a press release announcing corporate updates, including clinical trial enrollment updates and anticipated upcoming milestones, as well as the Company's plans to present at the 43 rd Annual J.P. Morgan Healthcare Conference. A copy of the press release is filed as Exhibit 99.1 hereto and is incorporated by reference herein. Item9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by Nuvalent, Inc. on January 13, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Nuvalent, Inc. Date: January 14, 2025 By: /s/ Deborah Miller Deborah Miller, Ph.D. Chief Legal Officer and Secretary